Imidazoline receptor I1 subtype (I1-imidazoline receptor (I1R))

The Imidazoline receptor I1 subtype is a putative G protein-coupled receptor primarily located on the plasma membrane of neurons within the reticular formation, dorsomedial medulla oblongata, adrenal medulla, renal epithelium, pancreatic islets, platelets, and prostate. It plays a crucial role in inhibiting sympathetic nervous system activity to lower blood pressure. The antihypertensive effects of drugs like clonidine and moxonidine are largely mediated through this target. Activation leads to signal transduction involving phospholipase C-mediated production of diacylglycerol—distinct from alpha2-adrenoceptors—and results in reduced plasma catecholamines. Therapeutically relevant for cardiovascular diseases such as hypertension—and potentially beneficial for metabolic syndrome—the I1-imidazoline receptor has been shown to improve glucose tolerance without impairing insulin secretion (unlike alpha2-adrenoceptor agonists). Its endogenous ligands are not fully established; agmatine has been proposed as one candidate. While its molecular identity remains incompletely defined ("orphan" status), its pharmacological profile is well characterized by selective ligand binding studies.

Other names

I1-imidazoline receptorI1RImidazoline binding site type 1

Central inhibition of sympathetic outflow, leading to decreased blood pressure by reducing plasma catecholamine levels through central mechanisms in the brainstem, especially the rostral ventrolateral medulla. This is mediated by agonists such as clonidine and moxonidine acting on the I1-imidazoline receptor, which triggers intracellular signaling cascades involving phospholipase C activation and diacylglycerol production.